Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Glushakov, Alexander V ^a   Robbins, Sean W ^a   Bracy, Connor L ^a   Narumiya, Shuh ^b   Doré, Sylvain ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

AL 8810; Controlled cortical impact; G protein coupled receptors; Glial fibrillary astrocytic protein; Knockout mice; Prostaglandin F2a receptor; Traumatic brain injury

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; PROSTAGLANDIN F2 ALPHA; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

AGED; ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN DAMAGE; BRAIN EDEMA; BRAIN HEMATOMA; BRAIN REGION; BRAIN SIZE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; GRIP STRENGTH; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; SCORING SYSTEM; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN; BRAIN INJURY; DISEASE MODEL; DRUG ANTAGONISM; KNOCKOUT MOUSE; MAZE TEST; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; BRAIN INJURIES; DINOPROST; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; RECEPTORS, PROSTAGLANDIN;

EID: 84886739429     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-132     Document Type: Article

References (84)

1. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008, 25:719-738.
2. McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest 1996, 74:315-342.
3. Loane DJ, Faden AI. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 2010, 31:596-604.
4. Kochanek PM, Bramlett H, Dietrich WD, Dixon CE, Hayes RL, Povlishock J, Tortella FC, Wang KK. A novel multicenter preclinical drug screening and biomarker consortium for experimental traumatic brain injury: operation brain trauma therapy. J Trauma 2011, 71:S15-S24.
5. Bazan NG, de Turco EB R, Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J Neurotrauma 1995, 12:814.
6. Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011, 63:471-538.
7. Mohan S, Ahmad AS, Glushakov AV, Chambers C, Doré S. Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol 2012, 3:145.
8. Doré S. GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor. Trends Pharmacol Sci 2006, 27:458-460.
9. Toti P, DEF C, Schurfeld K, Stumpo M, Bartolommei S, Lombardi A, Petraglia E, Buonocore G. Cyclooxygenase-2 immunoreactivity in the ischemic neonatal human brain. An autopsy study. J Submicrosc Cytol Pathol 2001, 33:245-249.
10. Tomimoto H, Akiguchi I, Wakita H, Lin JX, Budka H. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol (Berl) 2000, 99:26-30.
11. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, Budka H. A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol (Berl) 2002, 104:601-607.
12. Cernak I, O'Connor C, Vink R. Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats. Clin Exp Pharmacol Physiol 2001, 28:922-925.
13. Kunz T, Marklund N, Hillered L, Oliw EH. Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J Neurotrauma 2002, 19:1051-1064.
14. Cernak I, O'Connor C, Vink R. Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats. Exp Brain Res 2002, 147:193-199.
15. Dash PK, Mach SA, Moore AN. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J Neurotrauma 2000, 17:69-81.
16. Strauss KI, Barbe MF, Marshall RM, Raghupathi R, Mehta S, Narayan RK. Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J Neurotrauma 2000, 17:695-711.
17. Homayoun P, Parkins NE, Soblosky J, Carey ME, Rodriguez De Turco EB, Bazan NG. Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols. Neurochem Res 2000, 25:269-276.
18. Homayoun P, Rodriguez De Turco EB, Parkins NE, Lane DC, Soblosky J, Carey ME, Bazan NG. Delayed phospholipid degradation in rat brain after traumatic brain injury. J Neurochem 1997, 69:199-205.
19. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, Panikashvili D, Shohami E, Jansen SA, Narayan RK, Strauss KI. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 2005, 56:590-604.
20. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004, 351:1707-1709.
21. Kim YT, Moon SK, Maruyama T, Narumiya S, Doré S. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol Dis 2012, 48:58-65.
22. Saleem S, Ahmad AS, Maruyama T, Narumiya S, Doré S. PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res 2009, 15:62-70.
23. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther 1999, 290:1278-1284.
24. Yu S, Kaneko Y, Bae E, Stahl CE, Wang Y, van Loveren H, Sanberg PR, Borlongan CV. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain Res 2009, 1287:157-163.
25. Clark W, Gunion-Rinker L, Lessov N, Hazel K. Citicoline treatment for experimental intracerebral hemorrhage in mice. Stroke 1998, 29:2136-2140.
26. Ahmad AS, Saleem S, Ahmad M, Doré S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006, 89:265-270.
27. Maeda K, Hata R, Hossmann KA. Regional metabolic disturbances and cerebrovascular anatomy after permanent middle cerebral artery occlusion in C57black/6 and SV129 mice. Neurobiol Dis 1999, 6:101-108.
28. Majid A, He YY, Gidday JM, Kaplan SS, Gonzales ER, Park TS, Fenstermacher JD, Wei L, Choi DW, Hsu CY. Differences in vulnerability to permanent focal cerebral ischemia among - 3 common mouse strains. Stroke 2000, 31:2707-2714.
29. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke 2009, 40:e50-e52.
30. Barone FC, Knudsen DJ, Nelson AH, Feuerstein GZ, Willette RN. Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. J Cereb Blood Flow Metab 1993, 13:683-692.
31. Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurotherapeutics 2010, 7:366-377.
32. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J Cereb Blood Flow Metab 2004, 24:133-150.
33. Diaz-Arrastia R, Agostini MA, Frol AB, Mickey B, Fleckenstein J, Bigio E, Van Ness PC. Neurophysiologic and neuroradiologic features of intractable epilepsy after traumatic brain injury in adults. Arch Neurol 2000, 57:1611-1616.
34. Sutton RL, Lescaudron L, Stein DG. Unilateral cortical contusion injury in the rat: vascular disruption and temporal development of cortical necrosis. J Neurotrauma 1993, 10:135-149.
35. Matsushita Y, Shima K, Nawashiro H, Wada K, Tsuzuki N, Miyazawa T. Real time monitoring of glutamate following fluid percussion brain injury with hypoxia in the rat. Acta Neurochir Suppl 2000, 76:207-212.
36. Willmore LJ, Triggs WJ. Iron-induced lipid peroxidation and brain injury responses. Int J Dev Neurosci 1991, 9:175-180.
37. Doi T, Ueda Y, Tokumaru J, Mitsuyama Y, Willmore LJ. Sequential changes in AMPA and NMDA protein levels during Fe(3+)-induced epileptogenesis. Brain Res Mol Brain Res 2001, 92:107-114.
38. Muller K, Krieg P, Marks F, Furstenberger G. Expression of PGF2α receptor mRNA in normal, hyperplastic and neoplastic skin. Carcinogenesis 2000, 21:1063-1066.
39. Li DY, Varma DR, Chemtob S. Up-regulation of brain PGE2 and PGF2α receptors and receptor-coupled second messengers by cyclooxygenase inhibition in newborn pigs. J Pharmacol Exp Ther 1995, 272:15-19.
40. Li DY, Varma DR, Chemtob S. Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs. Br J Pharmacol 1994, 112:59-64.
41. Carlson NG. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res 2003, 71:79-88.
42. Kitanaka J, Onoe H, Baba A. Astrocytes possess prostaglandin F2 alpha receptors coupled to phospholipase C. Biochem Biophys Res Commun 1991, 178:946-952.
43. Kim HJ, Chung JI, Lee SH, Jung YS, Moon CH, Baik EJ. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res 2008, 1193:153-161.
44. Hadhazy P, Malomvolgyi B, Magyar K. Endogenous prostanoids and arterial contractility. Prostaglandins Leukot Essent Fatty Acids 1988, 32:175-185.
45. Hayashi S, Park MK, Kuehl TJ. Relaxant and contractile responses to prostaglandins in premature, newborn and adult baboon cerebral arteries. J Pharmacol Exp Ther 1985, 233:628-635.
46. Egg D, Herold M, Rumpl E, Gunther R. Prostaglandin F2 alpha levels in human cerebrospinal fluid in normal and pathological conditions. J Neurol 1980, 222:239-248.
47. Hagen AA, Gerber JN, Sweeley CC, White RP, Robertson JT. Levels and disappearance of prostaglandin F2alpha in cerebral spinal fluid: a clinical and experimental study. Stroke 1977, 8:672-675.
48. Kostic VS, Djuricic BM, Mrsulja BB. Cerebrospinal fluid prostaglandin F2 alpha in stroke patients: no relationship to the degree of neurological deficit. Eur Neurol 1984, 23:291-295.
49. Desjardins P, Sauvageau A, Bouthillier A, Navarro D, Hazell AS, Rose C, Butterworth RF. Induction of astrocytic cyclooxygenase-2 in epileptic patients with hippocampal sclerosis. Neurochem Int 2003, 42:299-303.
50. Wolfe LS, Mamer OA. Measurement of prostaglandin F2alpha levels in human cerebrospinal fluid in normal and pathological conditions. Prostaglandins 1975, 9:183-192.
51. Tamai I, Takei T, Maekawa K, Ohta H. Prostaglandin F2 alpha concentrations in the cerebrospinal fluid of children with febrile convulsions, epilepsy and meningitis. Brain Dev 1983, 5:357-362.
52. Cendes F. Febrile seizures and mesial temporal sclerosis. Curr Opin Neurol 2004, 17:161-164.
53. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol 2007, 35:984-999.
54. Wislicki L. Systemic adverse reactions to prostaglandin F2 (PGF2 alpha, dinoprostone, prostin F2 alpha, prostalmon F). Int J Biol Res Pregnancy 1982, 3:158-160.
55. Sederberg-Olsen J, Olsen CE. Prostaglandin-oxytocin induction of mid-trimester abortion complicated by grand mal-like seizures. Acta Obstet Gynecol Scand 1983, 62:79-81.
56. Lyneham RC, Low PA, McLeod JC, Shearman RP, Smith ID, Korda AR. Convulsions and electroencephalogram abnormalities after intra-amniotic prostaglandin F2a. Lancet 1973, 302:1003-1005.
57. Shearman RP, Lyneham RC, Walsh JC, Itzkowic D, Shutt DA. Electroencephalographic changes after intra-amniotic prostaglandin F2alpha and hypertonic saline. Br J Obstet Gynaecol 1975, 82:314-317.
58. Rantala H, Tarkka R, Uhari M. Systematic review of the role of prostaglandins and their synthetase inhibitors with respect to febrile seizures. Epilepsy Res 2001, 46:251-257.
59. Climax J, Sewell RD. Modification of convulsive behaviour and body temperature in mice by intracerebroventricular administration of prostaglandins, arachidonic acid and the soluble acetylsalicylic acid salt lysine acetylsalicylate. Arch Int Pharmacodyn Ther 1981, 250:254-265.
60. Bhattacharya SK, Sanyal AK. Inhibition of pentylenetetrazol-induced convulsions in rats by prostaglandin E1: role of brain monoamines. Psychopharmacology (Berl) 1978, 56:235-237.
61. Bhattacharya SK, Sanyal AK. Prostaglandin E1-induced potentiation of the anticonvulsant action of phenobarbitone in the rat. Role of brain monoamines. Prostaglandins Med 1978, 1:159-164.
62. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 1999, 843:118-129.
63. Ellis EF, Wright KF, Wei EP, Kontos HA. Cyclooxygenase products of arachidonic acid metabolism in cat cerebral cortex after experimental concussive brain injury. J Neurochem 1981, 37:892-896.
64. Dhillon HS, Donaldson D, Dempsey RJ, Prasad MR. Regional levels of free fatty acids and Evans blue extravasation after experimental brain injury. J Neurotrauma 1994, 11:405-415.
65. Beaumont A, Marmarou A, Hayasaki K, Barzo P, Fatouros P, Corwin F, Marmarou C, Dunbar J. The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury. Acta Neurochir Suppl 2000, 76:125-129.
66. Wang KK, Larner SF, Robinson G, Hayes RL. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol 2006, 19:514-519.
67. Reid WM, Rolfe A, Register D, Levasseur JE, Churn SB, Sun D. Strain-related differences after experimental traumatic brain injury in rats. J Neurotrauma 2010, 27:1243-1253.
68. Tan AA, Quigley A, Smith DC, Hoane MR. Strain differences in response to traumatic brain injury in Long-Evans compared to Sprague-Dawley rats. J Neurotrauma 2009, 26:539-548.
69. Fox GB, LeVasseur RA, Faden AI. Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: implications for gene targeting approaches to neurotrauma. J Neurotrauma 1999, 16:377-389.
70. Steward O, Schauwecker PE, Guth L, Zhang Z, Fujiki M, Inman D, Wrathall J, Kempermann G, Gage FH, Saatman KE, et al. Genetic approaches to neurotrauma research: opportunities and potential pitfalls of murine models. Exp Neurol 1999, 157:19-42.
71. Schauwecker PE, Steward O. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci USA 1997, 94:4103-4108.
72. Tong W, Igarashi T, Ferriero DM, Noble LJ. Traumatic brain injury in the immature mouse brain: characterization of regional vulnerability. Exp Neurol 2002, 176:105-116.
73. Baskaya MK, Rao AM, Dogan A, Donaldson D, Dempsey RJ. The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. Neurosci Lett 1997, 226:33-36.
74. Duvdevani R, Roof RL, Fulop Z, Hoffman SW, Stein DG. Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role?. J Neurotrauma 1995, 12:65-75.
75. Baskaya MK, Dogan A, Rao AM, Dempsey RJ. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. J Neurosurg 2000, 92:448-452.
76. Moser VC. Functional assays for neurotoxicity testing. Toxicol Pathol 2011, 39:36-45.
77. Kuhtz-Buschbeck JP, Stolze H, Golge M, Ritz A. Analyses of gait, reaching, and grasping in children after traumatic brain injury. Arch Phys Med Rehabil 2003, 84:424-430.
78. Golge M, Muller M, Dreesmann M, Hoppe B, Wenzelburger R, Kuhtz-Buschbeck JP. Recovery of the precision grip in children after traumatic brain injury. Arch Phys Med Rehabil 2004, 85:1435-1444.
79. Toh H, Ichikawa A, Narumiya S. Molecular evolution of receptors for eicosanoids. FEBS Lett 1995, 361:17-21.
80. Singh N, Ma B, Leonardo CC, Ahmad AS, Narumiya S, Doré S. Role of PGE2 EP1 receptor in intracerebral hemorrhage-induced brain injury. Neurotox Res 2013, 24:549-559.
81. Ahmad AS, Zhuang H, Echeverria V, Doré S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 2006, 23:1895-1903.
82. Ahmad AS, Kim YT, Ahmad M, Maruyama T, Doré S. Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox Res 2008, 14:343-351.
83. Ahmad M, Saleem S, Shah Z, Maruyama T, Narumiya S, Doré S. The PGE2 EP2 receptor and its selective activation are beneficial against ischemic stroke. Exp Transl Stroke Med 2010, 2:12.
84. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Doré S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 2005, 1066:71-77.